Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02588261
Title A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Acronym SOLAR
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS


No variant requirements are available.